The role of dopamine and norepinephrine in depression

Primary Psychiatry

Volumn 14, Issue 5, 2007, Pages 21-23

  Robinson, Donald S ^a  

^a Worldwide Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOPAMINE; MONOAMINE OXIDASE INHIBITOR; NOMIFENSINE; NORADRENALIN; PLACEBO; REBOXETINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DEPRESSION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MEDICAL RESEARCH; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOPHYSIOLOGY; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

EID: 34249069921     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry. 2006;67(suppl 6):3-8.
2. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327-337.
3. Nierenberg AA, DeCocco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):5-9.
4. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396-404.
5. Thase ME. Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry. 2003;64(suppl 2):3-7.
6. Nemeroff CB, Schatsberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002;36(4):106-132.
7. Nutt DJ, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. In press.
8. Randrup A, Munkvad I, Pog R, et al. Mania, depression, and brain dopamine. In: Essman W, Valzelli L, eds. Current Developments in Psychopharmacology, Volume 2. New York, NY: Spectrum Publications; 1975:206-248.
9. Meyer JH, McNeely HE, Sagrati S, et al. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission study. Am J Psychiatry. 2006:163(9):1594-1602.
10. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int J Psychopharmacol. 1997;12(suppl 3):S7-S14.
11. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull. 2002;36(3):124-138.
12. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12(3):185-219.
13. Stahl SM, Zhang L, Damatarca C, Grady M, Brain circuits determine destiny in depression: a novel approach to the pharmacology of wakefulness, fatigue, and executive function in major depressive disorder. J Clin Psychiatry. 2003;64(suppl 14):6-17.